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Abstract: 
 
This article introduces and reviews the history of the construct of schizotypy for the special 
section appearing in the journal. Schizotypy offers a useful construct for understanding the 
etiology, development, and expression of schizophrenia-spectrum psychopathology and a 
unifying construct for linking a broad continuum of clinical and subclinical manifestations. The 
article reviews the descriptive psychopathology roots of schizotypy, Meehl and Claridge’s 
classical formulations of the construct (including the debate about dimensional vs taxonic 
structure), and the need for a comprehensive, multidimensional model of schizotypy. The article 
briefly reviews the wide empirical literature supporting schizotypy and also examines several 
criticisms and misconceptions about the construct and research methods used to assess it. 
Finally, the article offers several suggested goals for future schizotypy research. 
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Article: 
 
Overview 
 
Schizotypy offers a useful and unifying construct for understanding schizophrenia-spectrum 
psychopathology. Useful in that it has explanatory power for understanding the development, 
expression, trajectory, risk and resilience, and treatment of schizophrenia-spectrum conditions, as 
well as for understanding variation in normal behavior, and unifying because it encompasses a 
broad spectrum of conditions—schizophrenia, related psychotic disorders, spectrum personality 
disorders, the prodrome, and subclinical expressions—under a single conceptual framework. 
Furthermore, schizotypy allows us to examine the etiological and developmental pathways 
underlying schizophrenia-spectrum psychopathology while minimizing many of the confounding 
effects that complicate the study of patients. However, the construct of schizotypy has suffered 
from the lack of a clear identity, as well as from conflicting identities in the literature, and the 
term is often used interchangeably with a variety of other descriptors. Nevertheless, schizotypy is 
an increasingly studied construct with a recent PsychInfo search (completed July 22, 2014) of the 
term indicating more than 1100 publications (including more than 400 since 2010). This brief 
review traces the history of schizotypy, differentiates it from related constructs, attempts to offer 
an integrative definition, addresses criticisms regarding the construct, and offers 
recommendations for future studies of schizotypy. 
 
Brief History of Schizotypy 
 
The term schizotypy was introduced more than 60 years ago to describe a broad phenotype of 
schizophrenic–like psychopathology and impairment. However, the origins of schizotypy date 
back at least another half century, and drew from both clinical and personality traditions. In the 
clinical domain, Kraepelin1 and Bleuler2 described schizophrenic–like traits in patients prior to 
their illness and in the relatives of patients. Kraepelin described these mild and subclinical 
symptoms as precursors to dementia praecox. However, he also suggested that psychotic–like 
experiences in relatives could signify an arrested form of the illness. Bleuler vividly described 
that “entirely crazy acts in the midst of normal behavior” can precede the development of 
schizophrenia2 (p. 252). The descriptive psychopathology literature includes numerous reports 
that mild forms of schizophrenia often appear in the nonpsychotic relatives of patients3–6 and 
precede the onset of clinical psychosis, although they often represent stable expressions that do 
not advance into full-blown disorders.7,8 Furthermore, the early and mid-20th century offered a 
number of schizophrenic–like conditions such as borderline, simple, ambulatory, and 
pseudoneurotic schizophrenia that captured characteristics of schizotypy.9 
 
Rado10 initially introduced the term schizotype to represent the schizophrenic phenotype, based 
upon his observations that there was a continuum of schizophrenic–like behavioral impairment. 
He indicated that the liability for schizophrenia was genetically driven and that this vulnerability 
resulted in impairment ranging from mild to fully schizophrenic. Meehl11,12 posited that a single 
dominant “schizogene” (in conjunction with other genetic potentiators) produced a 
neurointegrative defect referred to as schizotaxia that was necessary, although not sufficient, for 
the development of schizotypy (and by extension, schizophrenia). He viewed schizotypy as the 
personality organization that resulted from schizotaxia and conveyed vulnerability for the 
development of schizophrenia. Meehl’s13 checklist provided a rich description of schizotypic 
signs and symptoms such as cognitive slippage, anhedonia, and magical ideation. He 
substantially updated his original model by introducing hypokrisia (a neuronal level aberration 
that characterizes schizotaxia), diminishing the role of anhedonia, and expanding the impact of 
cognitive slippage and the contribution of polygenetic potentiators.12 Note that Lenzenweger14 
provided a comprehensive review of Meehl’s model of schizotypy. 
 
Meehl described that schizotypy is taxonic in nature, suggesting that approximately 10% of the 
population is schizotypic and that about 10% of schizotypes decompensate into schizophrenia 
(arriving at the 1% lifetime prevalence rate of schizophrenia). However, his taxonic formulation 
of schizotypy was based upon his single-gene model of schizotaxia, schizotypy, and 
schizophrenia that ultimately has not received support in the literature, eg,15,16, which currently 
conceptualizes schizophrenia as a complex, heterogeneous, and polygenic disorder (or family of 
disorders).17 Note that Meehl viewed that polygenetic potentiators could increase or decrease the 
likelihood of a schizotypic individual developing schizophrenia, but at the core of his model was 
a single gene that was necessary, albeit not sufficient, for schizophrenia to develop. More than a 
dozen studies have employed taxometric analyses to study the structure of schizotypy primarily 
employing questionnaire measures. The majority of these studies, eg,18,19 provided at least partial 
support for a schizotypy taxon (or taxa) with base rates in nonclinical samples generally 
approximating Meehl’s 10% estimate; although there have been notable exceptions.20,21 
Widiger22 raised concerns about taxonic models of psychopathology given that mental disorders 
likely result from multifactorial genetic and nongenetic origins that are inconsistent with such 
models. Thus, support for taxonic models of schizotypy requires a compelling etiological 
conceptualization that provides a basis for discontinuity, not simply results of taxometric 
analyses. Edmundson and Kwapil23 discussed that the heterogeneity of schizotypy and 
schizophrenia also raises questions about the extent to which separate etiological processes are 
occurring and how many taxa may be represented in our current conceptualization of schizotypy. 
The issue of whether schizotypy is taxonic remains to be resolved, but we suggest that the search 
for a schizotypy taxon (or taxa) should be predicated on an etiological model that supports a 
discontinuity in nature. 
 
Lenzenweger14,24 has been a leading proponent of Meehl’s conceptualization that schizotypy is 
the latent personality organization that conveys liability for schizophrenia. He has supported the 
role of genetically driven schizotaxia, or neurodevelopmental disruptions, giving rise to 
schizotypy and argued for the role of secondary biopsychosocial “hits” that exacerbates risk for 
clinical manifestations.25 Lenzenweger24 described that schizotypy can be identified by 
familial/biological, clinical, and psychometric-laboratory index approaches. 
 
The study of schizotypy also derived from the field of individual differences. Claridge and 
colleagues, eg, 26,27 offered an alternative model of schizotypy that was built upon dimensional 
models of personality and psychopathology and conjectured that schizotypy is fully dimensional 
in nature and includes adaptive manifestations (see figure 1). Claridge contrasted his fully 
dimensional model with Meehl’s “quasi-dimensional” approach that viewed expressions of 
schizotypy as formes frustes of disease. Claridge’s model proposes that schizotypy results from a 
combination of genetic, environmental, and personality variations that are normally distributed in 
the general population. Like Meehl’s formulation, the fully dimensional model recognizes 
dimensionality of schizotypy in the clinical and subclinical ranges, but also argues for continuity 
of schizotypic traits that are part of normal individual differences expressed in the general 
population. Thus, Claridge argues that it includes the pathological, quasi-dimensional 
components, but also encompasses healthy manifestations (eg, creativity). Claridge and Beech27 
suggested that schizotypy can be thought of as analogous to trait anxiety that has expressions in 
the general population, but in its extreme forms results in clinical disorders. 
 
 
Figure 1. Diagram of the fully dimensional model of schizotypy from Claridge and Beech27. 
 
Schizotypy as a Multidimensional Construct 
 
Schizotypy and, by extension, schizophrenia are heterogeneous. This heterogeneity is apparent at 
the phenotypic level, with symptoms and impairment ranging from mild disruptions (eg, odd 
beliefs, mild withdrawal) to marked excesses (eg, hallucinations) and deficits (eg, formal thought 
disorder). Furthermore, this heterogeneity is evident at the etiological, developmental, and 
treatment-response levels, and the heterogeneity of schizotypy and schizophrenia appears to be 
characterized by a common multidimensional structure. Factor analytic studies suggest that 
positive, negative, and disorganized dimensions underlie schizophrenia28,29 and these dimensions 
have been replicated in nonclinically ascertained schizotypy.30–34 The positive or psychotic–like 
dimension is characterized by disruptions in the content of thought (ranging from odd beliefs and 
magical ideation to full-blown delusions), perceptual oddities in all senses (ranging from 
illusions to hallucinations), and suspiciousness and paranoia. The negative or deficit dimension is 
characterized by diminution in experiences including alogia, anergia, avolition, anhedonia, 
flattened affect, and disinterest in others and the world. The disorganization dimension includes 
disruptions in the ability to organize and express thoughts and behavior, ranging from mild 
disturbances in thinking and behavior to formal thought disorder and grossly disorganized 
actions. Note that although there is considerable support for a three-factor model of schizotypy 
and schizophrenia, there is not universal agreement on the number and nature of the dimensions, 
and other dimensions have been proposed including a separate paranoia factor, eg,35 and 
impulsive-nonconformity.36 
 
The reliable identification and measurement of these dimensions is essential for parsing the 
heterogeneity of schizotypy and schizophrenia. In fact, treating schizotypy and schizophrenia as 
homogenous constructs impedes our ability to understand the origins, development, and 
expression of these complex conditions.9 Consider the question of whether schizotypy is 
associated with substance abuse. Studies using dimensional37 and cluster38 approaches reported 
that positive schizotypy, but not negative schizotypy, is associated with elevated drug and 
alcohol use and impairment. Thus, failing to differentiate these dimensions and simply 
examining “homogenous” schizotypy suggests that conflicting results could occur depending 
upon the composition of the sample in terms of positive and negative characteristics. We offer 
substance abuse as one example (and recognize that there are more sophisticated questions to 
examine regarding schizotypy and substance abuse), but this pattern of differential associations 
with the schizotypy dimensions arises when considering numerous psychological characteristics 
such as affective expression, creativity, social functioning, neuroticism, and cognitive 
impairment. Furthermore, it is important to consider that these dimensions may involve distinct 
etiological and developmental pathways, given findings of distinct disruptions in brain systems 
and neurotransmitter functioning in positive, negative, and disorganized symptoms in 
schizophrenia, eg,39–41. 
 
An Integrative Definition of Schizotypy for Moving Forward 
 
Currently, there are numerous terms that are used to describe similar phenomena: schizotypy, 
schizotypal personality, psychosis proneness, psychotic–like experiences, anomalous 
experiences, as well as broad labels such as subclinical psychotic symptoms. In recent years, this 
terminology has expanded with descriptors of clinically indexed vulnerability for schizophrenia, 
such as the prodrome, basic symptoms, at risk mental states for psychosis, and attenuated 
psychotic symptoms syndrome recently introduced in Diagnostic and Statistical Manual of 
Mental Disorders (DSM)-542 as a condition for future research. Many of these newer syndromes 
are based upon attenuated forms of positive symptoms and are designed to index risk of 
transition into psychosis. 
 
These terms bring added refinement to our understanding of the etiology and development of 
schizophrenia-spectrum psychopathology. However, we also suggest that it can reflect a lack of 
clarity as they are often used interchangeably with schizotypy. The utility of schizotypy requires 
clear operationalization (that should also drive our measurement of the construct). The 
inconsistent definition of schizotypy and assumed interchangeability of terms hinders our ability 
to integrate findings across studies. We suggest that most of the constructs represented by these 
other terms (eg, the prodrome) can be considered relatively narrow expressions of the schizotypy 
continuum and often simply represent differences in severity of symptoms. For example, non–
disordered schizotypes, prodromal patients, schizotypal personality disordered patients, and 
psychotic patients may all experience positive symptoms such as odd beliefs, but in an increasing 
level of severity from magical ideation to full-blown delusions. 
 
We posit that schizotypy is a multidimensional unifying construct that represents the underlying 
vulnerability for schizophrenia-spectrum psychopathology that is expressed across a broad range 
of personality, subclinical, and clinical psychosis phenomenology.9 This model implies that the 
same etiological, developmental, and phenomenological processes underlie subclinical and 
clinical manifestations. Thus, schizotypy provides an ideal model for examining these processes 
and their development. As described above, we believe that a multidimensional conception of 
schizotypy is an essential aspect of this model and we suggest that a significant task for 
schizotypy researchers is to reach a consensus regarding this multidimensional structure. 
 
In sum, schizotypy offers a dynamic, multidimensional model that is not constrained by 
diagnostic boundaries. It is not meant to replace diagnostic categories such as schizotypal 
personality disorder, attenuated psychotic symptoms syndrome, or schizophrenia. However, it is 
suggested that these categories are subsumed within the schizotypy continuum. Put differently, 
schizophrenia is not considered as a separate entity from schizotypy, but rather as the most 
extreme expression of schizotypy. Even if there is not a universally agreed upon model of the 
multidimensional structure of schizotypy, it provides a useful framework for advancing the 
understanding of personality-psychopathology links in general and within the field of psychosis 
in particular, as well as for testing hypotheses concerning the etiology, risk, resilience, 
expression, and treatment of schizophrenia-spectrum conditions. We are not advocating that this 
conceptualization of schizotypy perfectly “carves nature at its joints;” however, we believe that 
clear operationalization is essential to guide measurement and provide the basis for construct 
validation. 
 
It is worth noting that traditional categorical diagnostic systems are increasingly embracing 
dimensional models of psychopathology. For example, DSM-5 eliminated the differentiation of 
mental disorders (Axis I) from personality disorders (Axis II) given evidence that there is a 
common underlying structure to all psychopathology. DSM-5 offers an explicit statement about 
the limitations of assessing personality pathology using narrowly defined independent categories 
in light of the problems of high comorbidity, diagnostic status change, shared dimensional 
structure across categories and commonality of genetic and environmental risk factors for what 
were formerly assumed to be distinct disorders. Although DSM-5 formally retained the 
categorical model of personality disorders used in previous editions, it offers a dimensional, 
psychologically based model of disordered personality that employs pathological traits from five 
personality domains. Thus, schizotypal personality disorder is defined as a prototype 
characterized by impairments in identity, self-direction, empathy, and/or intimacy, along with 
specific maladaptive traits in the domains of psychoticism and detachment. We believe that this 
is a great enhancement in the conceptualization of schizotypal personality disorder, although it 
does not fully consider the multidimensional nature of the disorder, which is comprised of 
positive, negative, and disorganized features. 
 
Support for a Multidimensional Model of Schizotypy 
 
Despite disagreements about the construct, the lack of a clear multidimensional 
operationalization, and numerous and sometimes inconsistent measurement tools, cross-sectional 
and longitudinal studies of schizotypy have demonstrated the utility of the construct in terms of 
capturing variance in both clinical and nonclinical samples. The other articles in this special 
section review the construct validation of schizotypy in greater detail, but we offer several 
examples of selected findings that demonstrate the explanatory power of schizotypy. Schizotypy 
is presumed to convey the underlying vulnerability for schizophrenia. Therefore, non–disordered 
high schizotypy individuals are presumed to demonstrate mild and transient signs of the 
symptoms and impairments seen in schizophrenia and to be at elevated risk for transitioning into 
schizophrenia-spectrum disorders. Furthermore, studies have increasingly made predictions and 
examined findings separately for different schizotypy dimensions. Numerous studies reported 
that non–disordered schizotypic individuals exhibit psychotic–like,43 prodromal,44 schizophrenia-
spectrum,45 and basic symptoms.46 Furthermore, longitudinal studies47–49 demonstrated that 
positive schizotypy is associated with the development of psychotic disorders and negative 
schizotypy is associated with the development of schizophrenia-spectrum disorders. Schizotypy 
is also associated with schizophrenic–like patterns of cognitive impairment,50–53 neurological soft 
signs,54 and impairments on assessments of thought disorder,55 social cognition,56 and other 
laboratory measures.57 Schizotypy is associated with schizophrenic–like impairment on 
neuroscience assessments including neuroimaging,58 EEG,59 and eye tracking.60 Schizotypy is 
also associated with distinct patterns of normal personality traits,37 impaired attachment,61 and 
creativity.62 In addition, recent studies have employed experience sampling methodology to 
validate the expression of schizotypy, including the experience of psychotic–like symptoms, in 
daily life.63 
 
Criticisms of the Construct of Schizotypy 
 
The processes of submitting manuscripts for peer review, presenting at psychology, psychiatry, 
and personality conferences, and late night conversations with colleagues have provided us with 
the opportunity to consider many criticisms about the construct of schizotypy and research 
methods used to assess it. We have attempted to summarize and respond to a sampling of the 
recurring concerns that we have encountered (some of which we believe have merit, others 
which may represent important misconceptions to be addressed). 
 
Criticism #1: Schizotypy Does Not Exist 
 
The initial criticism is not focused on the research method or findings, per se, but instead 
questions the validity (or even the very notion) of the construct of schizotypy. A pair of 
prominent psychosis-proneness researchers commented that when they presented their initial 
findings at a psychiatry meeting in the early 1980’s, they were told that “people either had 
schizophrenia or they didn’t—and that there was no middle ground.” Whereas schizophrenia was 
originally the province of psychiatry, schizotypy arose from psychology, and literature searches 
suggest that schizotypy was much more readily incorporated in the field of psychology than in 
psychiatry. Tsuang64 stressed the importance of expanding the concept of schizophrenia to 
include schizophrenia-spectrum disorders, as well as nonclinical manifestations of schizotaxia. In 
fact, Tsuang et al65 adapted Meehl’s term schizotaxia to describe the expression of 
neurodevelopmental vulnerability for schizophrenia—analogous to the use of schizotypy. 
Currently, most neurodevelopmental models of schizophrenia either explicitly or implicitly 
recognize that the vulnerability for schizophrenia is expressed across a continuum66—consistent 
with the formulation of schizotypy. 
 
Criticism #2: There Is Not a Clear A Priori Model of the Multidimensional Structure of 
Schizotypy 
As noted above, the heterogeneity of schizotypy appears to be represented in a multidimensional 
structure; however, the historical models of schizotypy did not articulate such a factor structure 
and tended to refer to schizotypy as an omnibus construct. Furthermore, whereas most current 
measures assess schizotypy in a multidimensional fashion, in many cases this factor structure 
was the result of exploratory, post hoc examinations, not a priori conceptualizations. Thus we 
have a situation in which researchers often acknowledge and assess schizotypy as 
multidimensional, but their conceptual understanding of this structure may be driven more by the 
choice of their measure than by an a priori conceptual model driving the development and choice 
of measures.67 We suggest that the utility of schizotypy depends upon the development of a clear 
theoretical model that articulates its multidimensional structure. 
 
Criticism #3: The Study of Schizotypy Is Largely Limited to Research Using Psychometric 
Inventories and Involving College Student Samples 
 
Psychometric assessments have been widely (and effectively) used to assess schizotypy, often in 
conjunction with other questionnaire, interview, and laboratory measures. Nevertheless, a 
number of legitimate criticisms can be leveled at these measures: as noted above many of these 
scales (and their multidimensional structures) do not adequately tap current conceptualizations of 
schizotypy, the measures have different multidimensional structures and purportedly comparable 
factors across measures often are measuring different constructs, almost none of these measures 
were developed with modern measurement models such as item response theory and their 
psychometric properties are not always ideal.67 However, psychometric inventories are relatively 
inexpensive and noninvasive, and they provide a useful method for “getting our foot in the 
schizotypy door” and a promising tool for aiding in the identification of biological markers. Thus 
the psychometric method seems sound, but there is a need to develop new measures based upon 
current conceptual models of schizotypy and employing modern measurement tools. Regarding 
the second part of the criticism, the study of schizotypy (and especially the psychometric study) 
has often relied on college student samples. A recent and notable exception is the longitudinal 
research by Blanchard and colleagues45 examining social anhedonia in a community sample. 
Critics suggest that the use of so-called “analog samples” is invalid because college students 
have a lower risk for developing schizophrenia. However, as Lenzenweger24 points out, 
schizotypy is not simply an analog of schizophrenia, but presumes to indicate carriers of genuine 
liability. Note that the current model of schizotypy (and data from longitudinal studies) implies 
that there is meaningful variance associated with schizotypy that can be measured in college 
student samples. If we hypothesize a continuum of schizotypy anchored by schizophrenia at the 
extreme end, we would expect that comparable (albeit milder and transient) expressions of 
schizophrenic phenomenology will be expressed across the continuum—and that we can predict 
and measure this variation across the continuum (including in college student samples). In a 
sense, the use of these samples presents a conservative approach, given that they are expected to 
have an excess of protective factors and to include future patients with relatively good premorbid 
adjustment (as this ascertainment strategy generally fails to capture schizotypes with early onset 
and poor premorbid functioning). The successful findings with college student samples 
encourage extending this method to screening broader samples and integrating it with clinical 
and family risk studies. 
 
Criticism #4: Longitudinal Studies of Schizotypy Fail to Identify Individuals Who Transition 
into Schizophrenia at an Appreciable Rate 
 
This is a common misconception that we suggest is twice erroneous. First of all, it appears to be 
based upon an invalid assumption that schizotypy is equated with the prodrome and incipient 
transition into psychosis. On the contrary, the present operationalization of the construct implies 
that most schizotypes are not expected to decompensate into spectrum disorders. As noted above, 
Meehl speculated that only about 10% of schizotypes will transition into schizophrenia. We do 
not offer Meehl’s speculation as an epidemiological standard, but rather as an illustration that 
although schizotypy conveys risk for schizophrenia and related disorders, it (thankfully) does not 
invariably result in psychiatric illness. It also means that schizotypic individuals who remain 
compensated are of just as much scientific import as their decompensated peers in that they may 
inform us about protective factors. 
 
Criticisms about transition rates also fail to fully examine the extant data. An unnamed colleague 
once mentioned that it was a shame that the Wisconsin47 longitudinal study “only found a 5% 
rate of psychosis at the follow-up.” We suggest that there are two problems with this conclusion. 
First of all, this rate was found in a high-functioning sample who at an age of 30 were only mid-
way through the window of risk for developing schizophrenia. Secondly, when multiple 
predictors were considered, the rate of psychosis increased dramatically (eg, in the Chapman et 
al study, 40% of participants identified by the combination of the Magical Ideation and Revised 
Social Anhedonia Scales, and who exhibited moderate psychotic–like experiences at the initial 
assessment met criteria for psychotic disorders at the follow-up assessment).47 Likewise, 
Kwapil48 reported that a quarter of his 30-year-old sample identified solely by social anhedonia 
met criteria for schizophrenia-spectrum disorders. Strikingly, these rates are higher than those 
typically found in first degree relatives of schizophrenic patients. 
 
A related criticism is that schizotypy studies, and particularly those employing the psychometric 
method, are beset by a serious problem with false positives. Obviously, this issue depends in 
large part on the construct being measured. Again, if the target is schizophrenia or incipient 
illness, the method does result in many false positives. However, if the target is schizotypy in 
line with the conceptualizations drawing on Meehl or Claridge, this remains an open question—
open in large part because we lack a gold standard and must rely on construct validation of an 
open construct. In fact, this criticism seems to confuse construct validity (appropriate in the case 
of schizotypy), with a diagnostic–based criterion validity (seemly more suitable in the case of 
prodromal cases who are on the brink of schizophrenia). Unfortunately, construct validity 
demands more patience to formulate and test hypotheses about the construct than does criterion 
validity. For example, in the Wisconsin follow-up study, between 5% and 40% of the at-risk 
samples were psychotic at age 30. What does this mean about the remaining 60–95% of the 
sample? Lacking a crystal ball (and further longitudinal assessments), we do not know if they are 
false positives, if they are schizotypes who will decompensate in the future, or if they are 
schizotypes who are and will remain compensated (likely due to protective factors that we fail to 
recognize at this point). Thus we strongly advocate for continued longitudinal studies of existing 
samples, as well as the development of new longitudinal studies to examine both risk and 
resilience in schizotypic young adults. Furthermore, it would be profitable to examine schizotypy 
and risk for schizophrenia-spectrum disorders in the offspring of schizotypic participants (such 
as the children of the participants in the Chapmans’ longitudinal study). 
 
Where Are We Now, Where Should We Go? 
 
The descriptive psychopathology tradition, traditional diagnostic nomenclature, prodromal 
models, psychosis-proneness models, and the personality psychology literature, all support the 
idea of a broader continuum of schizophrenia-spectrum psychopathology. Schizotypy provides a 
promising, useful, and integrative construct for capturing pathological and subclinical variation 
across this continuum. Furthermore, we believe it offers an important tool for increasing the 
power of genetic studies and for enhancing the search for candidate endophenotypes. We suggest 
that the blueprint for advancement of this construct should include: clearer articulation of the 
theoretical model of schizotypy (which we believe is an important goal of this special section), 
better definition of the multidimensional structure of schizotypy, need for the development of 
better measures that reflect current conceptual models and employ modern measurement 
techniques, and the need to resolve dimensional vs taxonic debate. We believe that the starting 
point for moving forward is to develop a clear and comprehensive operationalization of 
schizotypy. The number of published studies on schizotypy is dramatically increasing, but these 
studies all too often either lack a clear operationalization of the construct or have conflicting 
characterizations. We have offered a brief description in this overview, but a more 
comprehensive model that characterizes etiology, development, phenomenology, and 
associations with related constructs is essential. As noted previously, we believe a strength of the 
schizotypy construct is that it unifies a broad range of conditions. Obviously a consensus model 
would be powerful, but we believe that clearly operationalized competing models would also 
energize the field. The bottom line is that such theoretical models should provide the basis of 
measurement and construct validation. Given the development of clear and testable models, the 
next step is to develop measures that are tightly linked to these models. We are strong advocates 
that psychometric assessment provides a promising point of entry for assessing schizotypy and 
strongly recommend that new questionnaire and interview measures should follow from these 
new conceptualizations. Given these conceptual and measurement advances, we would argue for 
an integrative research strategy that examines developmental processes across the range of 
subclinical and clinical expression of schizotypy. Specifically this would focus on: (1) 
identification of candidate genes and their mode of action in schizotypy and risk and resilience 
for clinical disorders, (2) identification of environmental factors (eg, stress, trauma, attachment) 
and gene × environment interactions underlying schizotypy and the development of clinical 
disorders, (3) identification of cognitive, neurological, and behavioral endophenotypes that 
characterize schizotypy broadly defined, (4) identification and differentiation of the processes 
underlying the positive, negative, and disorganized dimensions of schizotypy with a goal of 
developing interventions that minimize the likelihood of the development of clinical disorders 
and ameliorate impairment caused by clinical conditions. Again, we believe that schizotypy 
provides a unique, useful, and unifying construct for understanding the origins and development 
of schizophrenic psychopathology. 
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